Brind.

VYJUVEK Reports $127.3M Global Revenue, Cuts Expense Guidance

1 report, 1 independent Updated Nov 2
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

VYJUVEK reported global revenue of $127.3 million, which represents a 30% increase from $97.8 million reported in the third quarter of 2025. The company also authorized a $400 million share repurchase program. Non-GAAP expense guidance was lowered to a range of $155 million to $165 million, down from the previous range of $175 million to $195 million.

From aol.com

Why it matters

Some supportBrind's analysis of the reports

The company maintained a strong financial position, reporting $1.2 billion in cash and investments. US net revenue reached $95.3 million, supported by over 760 US reimbursement approvals. Despite the revenue growth, net income per diluted share decreased to $2.05 from $2.66 in the prior year period.

From aol.com

Who's involved

  • Suma KrishnanPresident of Research and Development at Krystal Biotech, Inc.
  • Christine WilsonSenior Vice President and Head of US Commercial at VYJUVEK

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped